ISRCTN72841333已完成不适用
Comprehensive studies of a new improved oral rehydration solution for diarrhoeal disease: physiological and molecular studies, clinical trials, and acceptability and efficacy studies in a rural south Indian community
Christian Medical College (India)0 个研究点目标入组 0 人开始时间: 2005年7月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In the adult study, all adult male patients presenting to the Emergency Service with acute severe watery diarrhoea of less than three days' duration, with moderate to severe dehydration, will be enrolled after informed written consent.
- •In a separate trial, male children aged six months to five years with diarrhoea (defined as more than three watery stools/24 hours) of three days or less, with mild or moderate dehydration, or those with severe dehydration who have received intravenous rehydration, will be enrolled after informed written consent from the parent.
排除标准
- •In the adult trial, subjects without clinical dehydration, those with presence of blood in stool, and presence of significant systemic illness unrelated to the diarrhoea, will be excluded.
- •In the children's trial, bloody diarrhoea, concurrent severe illness (such as pneumonia, meningitis or infections requiring antibiotics), and severe malnutrition Grade III and IV will be treated as exclusion criteria.
研究者
相似试验
已完成
1 期
Development and evaluation of a new oral care method to elederly and compromised patients with antimicrobial photodynamic therapyoral diseaseJPRN-UMIN000012504ational Center for Global Health and Medicine6
招募中
不适用
Developing an efficient and cost effective method for screening of oral cancer in IndiaCTRI/2019/02/017623Tata Trusts
已完成
4 期
Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute GastroenteritisDiarrheaNCT01467570Medical University of Warsaw147
进行中（未招募）
不适用
Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin (CB-01-05-MMX), administered as add-on therapy to oral mesalazine or other 5-ASA derivatives, in patients with active, left-sided, mild to moderate ulcerative colitis. A multicentre randomized, double-blind, comparative study versus placebo.Active left-sided, mild to moderate ulcerative colitisMedDRA version: 8.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2006-001782-42-HUCosmo Technologies Ltd120
进行中（未招募）
1 期
Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin (CB-01-05-MMX), administered as add-on therapy to oral mesalazine or other 5-ASA derivatives, in patients with active, left-sided, mild to moderate ulcerative colitis. A multicentre randomized, double-blind, comparative study versus placebo.EUCTR2006-001782-42-GBCosmo Technologies Ltd120